Since the World Health Organization identified artemisinin, the key ingredient of artemisinin-based combination therapies (ACTs), global demand for ACTs has increased. The World Health Organization noted that ACTs are the most effective malaria treatment available. ACTs allow for a more consistent supply than the existing botanical supply of artemisinin which is derived from the sweet wormwood plant that is harvested in just a few regions of the world. Its volatile cost and unpredictable supply has put antimalarial treatment out of reach for many people who are the most at risk. Multiple sources of high-quality artemisinin will strengthen the artemisinin supply chain, contribute to a more stable price, and ultimately ensure greater availability of treatment to people suffering from malaria.
The global pharmaceutical company, Sanofi, is now producing semisynthetic artemisinin in its factory in Italy that will be able to bolster the existing botanical supply and meet approximately one-third of the global demand for antimalarial treatment.
Reaching this point is important because promoting a steady and affordable supply of the drug is a critical part of our efforts to ultimately eradicate malaria and advance health equity.
– Essee Oruma
Sources: PATH, allAfrica